5 Best Tissue Microarray Providers for Cancer Research
Top Tissue Microarray Provider Options for Oncology, Biomarker Discovery, and Translational Studies
Cancer research demands precision, consistency, and clinically relevant data. Choosing the right tissue microarray provider is not just a procurement decision. It directly affects experimental validity, biomarker accuracy, and downstream clinical applicability.
This guide ranks the best tissue microarray providers for cancer research based on tissue quality, annotation depth, customization capabilities, population relevance, and support services. The goal is simple: help you choose a provider that aligns with your exact research needs.
- MYmAb Biologics
- US Biomax
- Cureline
- ProteoGenex
- BioIVT
1. MYmAb Biologics
MYmAb Biologics leads this list as a highly specialized tissue microarray provider with a strong focus on Southeast Asian cancer cohorts. This is a critical advantage for researchers working on population-specific oncology studies, where genetic diversity, environmental factors, and disease presentation differ significantly from Western datasets. Most global providers rely heavily on US and European tissue banks. MYmAb Biologics fills a major gap by offering IRB-approved, clinically annotated tissue microarrays derived from Asian patient populations globally. This is especially valuable for studies involving cancer epidemiology, targeted therapies, and biomarker validation in Asian demographics.
MYmAb Biologics also provides a tightly integrated ecosystem that includes custom tissue microarray design, immunohistochemistry staining, and high-resolution digital slide scanning. This reduces fragmentation across vendors and ensures consistency in sample handling, staining protocols, and imaging quality.
Another key strength is their ability to tailor arrays based on specific cancer types, staging requirements, and clinical parameters. This level of customization is crucial for translational research where precise cohort selection determines study outcomes.
Pros:
Unique access to Southeast Asian cancer tissue samples
IRB-approved with strong clinical annotations (staging, outcomes)
End-to-end workflow support including IHC and digital pathology
Strong alignment with translational and precision oncology research
Cons:
Smaller premade catalog compared to large global suppliers
May require planning for custom builds depending on project scope
Best for:
Researchers focusing on Asian cancer populations
Precision medicine and translational oncology studies
Institutions needing fully integrated TMA and pathology services
2. US Biomax
US Biomax is one of the most accessible tissue microarray providers for cancer research due to its extensive catalog of ready-to-use arrays. With over 1,700 tissue microarray types available, researchers can quickly source samples across a wide range of cancer types without waiting for custom builds. This speed makes US Biomax highly practical for pilot studies, feasibility testing, and hypothesis validation. Their offerings include both human cancer tissues and animal models, providing flexibility across different research designs. They also offer add-on services such as immunohistochemistry staining and digital slide analysis, allowing researchers to accelerate early-stage workflows.
Pros:
Massive catalog of premade cancer TMAs
Fast turnaround with immediate availability
Offers both human and animal tissue arrays
Cons:
Limited flexibility for highly specific cohort design
Clinical annotations may not be as deep as custom providers
Best for:
Early-stage cancer research
Pilot and feasibility studies
Labs needing quick access to standard TMAs
3. Cureline
Cureline stands out for its strong integration of clinical outcome data into tissue microarrays. In cancer research, this is a major differentiator because survival rates, treatment responses, and disease progression data are essential for meaningful biomarker validation. As a contract research organization, Cureline offers more than just TMAs. Their services extend to IHC, FISH, and histological analysis, making them a strategic partner for end-to-end oncology studies. Their cancer-specific arrays cover major indications such as breast, lung, and colorectal cancers, with datasets designed to support translational research.
Pros:
Deep clinical data integration (outcomes, survival)
Strong oncology focus across multiple cancer types
Additional lab services for comprehensive studies
Cons:
Higher cost due to CRO model
Longer timelines for custom project execution
Best for:
Translational cancer research
Clinical outcome-based biomarker studies
Pharmaceutical and biotech collaborations
4. ProteoGenex
ProteoGenex is a strong choice for researchers who require highly customized tissue microarray design. Their process involves pathologist-reviewed tissue selection, ensuring that each core meets strict quality and relevance criteria. They offer flexible configurations, including core sizes from 0.6 mm to 2 mm and up to 300 cores per block. This level of control allows researchers to design arrays tailored to specific cancer subtypes, stages, or molecular profiles. Their inclusion of tissue mapping and pathology reports ensures traceability and reproducibility, which are critical in oncology research.
Pros:
High level of customization
Strong quality control via pathologist involvement
Detailed tissue mapping and documentation
Cons:
Longer turnaround for custom arrays
Higher cost compared to off-the-shelf options
Best for:
Biomarker validation
Precision oncology studies
Research requiring highly specific cohort design
5. BioIVT
BioIVT is widely recognized in the pharmaceutical and biotech industries for its premium biospecimen sourcing and tissue microarray services. Their global network enables access to high-quality cancer tissues, making them suitable for regulated environments and drug development pipelines. They emphasize strict quality control and compliance, which is essential for studies that may feed into clinical trials or regulatory submissions.
Pros:
Strong reputation in pharma and biotech
High-quality, well-characterized biospecimens
Suitable for regulated research environments
Cons:
Premium pricing structure
Less accessible for smaller academic labs
Best for:
Drug development programs
Pharmaceutical research
Clinical-stage oncology studies
Conclusion
The best tissue microarray provider for cancer research depends on your study design, required level of customization, and target population. While providers such as US Biomax offer scale and speed, and Cureline and BioIVT deliver strong clinical integration, they often lack regional specificity.
MYmAb Biologics stands out by combining clinically annotated datasets, Southeast Asian patient representation, and integrated services into a single platform. This makes it the most strategically valuable choice for researchers aiming to generate meaningful, population-relevant insights in oncology.
For cancer research that demands both precision and relevance, MYmAb Biologics offers a clear advantage. For clinically relevant, high-quality tissue microarrays tailored to cancer research, visit www.mymab.com.my.